Document:

EX-10.11

 Exhibit 10.11 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [ *** ]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY
CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 EXCLUSIVE PATENT LICENSE AGREEMENT 

by and between 

PURETECH VENTURES LLC 

and 
 KARUNA
PHARMACEUTICALS, INC. 

 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [ *** ]) FROM THE EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 EXCLUSIVE PATENT LICENSE AGREEMENT

 This Agreement, effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between
PureTech Ventures LLC, a Delaware limited liability company (“PureTech”), and Karuna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). PureTech and the Company are sometimes referred to herein
individually as a “Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, PureTech is the owner of certain Patent Rights (as later defined herein) and has the right to grant licenses under said Patent Rights; 

WHEREAS, PureTech desires to have the Patent Rights developed and commercialized by the Company and is willing to grant a license thereunder; and 

WHEREAS, the Company desires to obtain a license under the Patent Rights and PureTech is willing to grant the same to the Company upon the terms and
conditions hereinafter set forth. 
 NOW, THEREFORE, PureTech and the Company hereby agree as follows: 

1. DEFINITIONS 
 1.1
“Affiliate” shall mean any legal entity (such as a corporation, partnership, or limited liability company) that is controlled by a Party. For purposes of this definition, the term “control” means as to such entity, direct
or indirect ownership of (i) more than fifty percent (50%) in the aggregate of the voting power of all outstanding shares entitled to vote at a general election of directors of such entity, (H) more than fifty percent (50%) of
the equity interests in such entity, or (iii) more than fifty percent (50%) of the assets of such entity. 
 1.2 “Field” shall
mean all uses and applications. 
 1.3 “Licensed Product” shall mean any product that cannot be manufactured, used, leased or sold, in
whole or in part, without infringing one or more Valid Claims under the Patent Rights. 
 1.4 “Net Sales” means [ *** ]. 

[ *** ] 
 1.5 “Patent Rights” shall mean all of
PureTech’s right, title and interest in: 
 (a) the United States patent applications listed on Appendix A, their foreign counterparts, and the
resulting patents; 
 (b) any divisionals, continuations,
continuation-in-part applications, continued prosecution applications, or any other application claiming priority to one or more of the patent applications listed on
Appendix A to the extent the claims are directed to subject matter specifically described in the patent applications listed on Appendix A, and the resulting patents; and 

(c) any patents resulting from reissues, reexaminations, extensions, or restorations (and their relevant international equivalents) of the patents described
in (a) and (b) above. 

 1.6 “Reporting Period” shall begin on the first day of each calendar quarter and end on the
last day of such calendar quarter. 
 1.7 “Sublicense Income” shall mean all consideration received by the Company or any of its Affiliates
from Sublicensees in exchange for the sublicensing of rights granted to the Company pursuant to Article 2 herein, but specifically excluding royalties. Sublicensing Income includes, without limitation, upfront payments, milestone payments, license
maintenance fees, research and development funding (subject to (a), below) and equity investments (whether in the form of stock purchase, options, warrants, convertible debt or other forms) (subject to (a), below) paid directly or indirectly to the
Company (or any of its Affiliates) from (or on behalf of) any Sublicensee. Notwithstanding the foregoing: 
 (a) funding of activities directly in
furtherance of Licensed Product research and clinical, regulatory and manufacturing process development are excluded from Sublicense Income; and 
 (b)
Sublicense Income shall not include amounts paid to the Company as an equity investment in the Company or any of its Affiliates (whether in the form of stock purchase, options, warrants or other forms) to the extent that the amount of such
investment (calculated in case of options, warrants and the like as if exercised and including all amounts due on exercise) does not involve any premium over fair market value of the equity investment. 

To avoid any doubt, Sublicensing Income extends to and includes consideration that is paid on the basis of rights (including covenants not to sue) under any
intellectual property licensed to the Company pursuant to Article 2 of this Agreement even if the Company structures its grant of rights to the Sublicensee so that the grant of rights under the Patent Rights formally occurs in a separate written
agreement from the grant of rights under other intellectual property of the Company relating to the Licensed Product. 
 1.8 “Sublicensee”
shall mean any non-Affiliate sublicensee of the rights granted the Company under Section 2.2. 
 1.9
“Term” shall mean the term of this Agreement, which shall commence on the Effective Date and shall remain in effect until the expiration or abandonment of all issued patents and filed patent applications within the Patent Rights,
unless earlier terminated in accordance with the provisions of this Agreement. 
 1.10 “Territory” shall mean worldwide. 

1.11 “Valid Claim” shall mean a claim of any filed patent application included within the Patent Rights which has not been held finally
revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction and which (i) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, (ii) has not
been withdrawn or abandoned, or (iii) has not been lost through an interference proceeding. 
 2. GRANT OF RIGHTS. 

2.1 License Grants. Subject to the terms of this Agreement, PureTech hereby grants to the Company for the Term a royalty-bearing exclusive license
(even as against PureTech) under the Patent Rights to research, develop, make, have made, use, offer for sale, sell, lease, import and otherwise exploit Licensed Products in the Field in the Territory. 

2.2 Sublicenses. The Company shall have the right to grant sublicenses of its rights hereunder. The Company shall incorporate terms and conditions into
such sublicense agreements sufficient to enable the Company to comply with this Agreement. Within [ *** ] following the execution thereof, the Company shall furnish PureTech with a fully signed photocopy of any sublicense agreement. 

2.3 No Additional Rights. Nothing in this Agreement shall be construed to confer any rights upon the Company by implication, estoppel or otherwise as
to any technology or patent rights of PureTech or any other entity other than the Patent Rights, regardless of whether such technology or patent rights shall be dominant or subordinate to any Patent Rights. 

 2.4 Due Diligence Obligations. The Company shall use diligent efforts, and shall cause its Affiliates
and any Sublicensees to use diligent efforts, to develop Licensed Products and to introduce Licensed Products into the commercial market; thereafter, the Company and its Affiliates and any Sublicensees shall maximize the commercial sales of such
Licensed Products. Specifically, the Company and its Affiliates and any Sublicensees shall fulfill the following obligations: 
 (a) Within [ *** ] of the
Effective Date, the Company shall initiate, defined as first dosing of patient, a trial using a Licensed Product where the primary outcome measure is a statistically significant separation by a Licensed Product from placebo on the positive and
negative symptom scale (PANSS) or equivalent scale that has previously been used as a primary endpoint for U.S. Food and Drug Administration registration for the treatment of schizophrenia and the total number of patients that will enroll in the
study is greater than [ *** ]. 
 (b) At any time prior to approval of a Licensed Product by the U.S. Food and Drug Administration, the Company shall not,
for any consecutive [ *** ] period, fail to initiate, defined as first dosing of patient, a human clinical study with a Licensed Product or make a regulatory submission to the U.S. Food and Drug Administration, the European Medicines Evaluation
Agency, or the Japanese Ministry of Health and Welfare seeking the marketing of a License Product for the treatment of a disease. 
 (c) The Company shall
not (i) become insolvent; (ii) make an assignment for the benefit of creditors; (iii) have a bona fide petition in bankruptcy filed for or against it, which petition is withdrawn or dismissed within [ *** ] of its filing; or
(iv) cease operations (at an activity level sufficient for the continued development of Products) for more than one [ *** ]. 
 In the event that
PureTech determines that the Company (or an Affiliate or Sublicensee) has failed to fulfill its obligations under this Section 2.4, then PureTech may treat such failure as a material breach in accordance with Section 11.2(b). 

3. ROYALTIES AND PAYMENT TERMS. 

3.1 Consideration for Grant of Rights. 
 (a) Running
Royalties. The Company shall pay to PureTech a running royalty of [ *** ] of annual Net Sales by the Company, its Affiliates and any Sublicensees. Running royalties shall be payable for each Reporting Period and shall be due to PureTech within [
*** ] of the end of each Reporting Period. 
 (b) Milestone Payments. The Company shall pay to PureTech the following milestone payments in
connection with the achievement of the following events by the Company, any of its Affiliates or any Sublicensee (each such event is hereafter referred to as a “Milestone”): 

(i) [ *** ] within [ *** ] following the commencement of a Phase III Clinical Trial of a Licensed Product; 

(ii) [ *** ] within [ *** ] following approval by the U.S. Food and Drug Administration, or any successor thereto, to offer for sale and sell (including any
necessary price approvals) any Licensed Product; 
 (iii) [ *** ] within [ *** ] following approval by the European Medicines Evaluation Agency or any other
European regulatory authority, or any successor thereto, to offer for sale and sell (including any necessary price approvals) any Licensed Product; and 

(iv) [ *** ] within [ *** ] following approval by the Japanese Ministry of Health and Welfare or, any successor entity to offer for sale and sell (including
any necessary price approvals) any Licensed Product. 
 (c) Sharing of Sublicense Income. The Company shall pay PureTech [ *** ] all Sublicense
Income received by the Company or its Affiliates, excluding running royalties on Net Sales of Sublicensees. Such amount shall he payable for each Reporting Period and shall be due to PureTech within [ *** ] of the end of each Reporting Period. 

 3.2 Payments. 

(a) Method of Payment. All payments under this Agreement shall be made payable to PureTech and sent to the address identified in Section 13.1.
Each payment should reference this Agreement and identify the obligation under this Agreement that the payment satisfies. 
 (b) Payments in U.S.
Dollars. All payments due under this Agreement shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in The Wall Street
Journal) for the last working day of the calendar quarter of the applicable Reporting Period. Such payments shall be without deduction of exchange, collection or other charges. Each Party is solely responsible for timely and properly filing and
payment of its own taxes of any kind and in any jurisdiction. All payments under this Agreement shall be made in full without any deduction or withholding for or on account of any tax unless such deduction or withholding is required by applicable
governmental laws, tax treaty, or regulations. Any tax required to be withheld by the Company under the laws of any foreign country for the account of PureTech shall be promptly paid by the Company for and on behalf of PureTech to the appropriate
governmental authority, and the Company shall use its best efforts to furnish PureTech with proof of payment of such tax together with official or other appropriate evidence issued by the applicable government authority. Any such tax actually paid
on PureTech’s behalf shall be deducted from royalty payments due PureTech. 
 (c) Late Payments. Any payments by the Company that are not paid
on or before the date such payments are due under this Agreement shall bear interest, to the extent permitted by law, at [ *** ] above the Prime Rate of interest as reported in The Wall Street Journal on the date payment is due. 

4. REPORTS AND RECORD KEEPING. 

4.1 Frequency of Reports. 
 (a) Before First
Commercial Sale. Prior to the first commercial sale of any Licensed Product, the Company shall deliver reports to PureTech annually, within [ *** ] the end of each calendar year, containing information concerning the progress of research and
development pertaining to the Licensed Product. 
 (b) Upon First Commercial Sale. The Company shall report to PureTech the date of first commercial
sale of a Licensed Product within [ *** ] of occurrence thereof in each country. 
 (c) After First Commercial Sale. After the first commercial sale
of a Licensed Product, the Company shall deliver reports to PureTech within [ *** ] of the end of each Reporting Period, containing information concerning the immediately preceding Reporting Period, as further described in Section 4.2. 

4.2 Content of Reports and Payments. Each report delivered by the Company to PureTech shall contain at least the following information for the
immediately preceding Reporting Period: 
 (a) the number of Licensed Products sold, leased or distributed by the Company, its Affiliates and any
Sublicensees to independent third parties in each country; 
 (b) the gross price charged by the Company, its Affiliates and any Sublicensees for each
Licensed Product; 
 (c) the calculation of Net Sales for the applicable Reporting Period in each country, including a listing of applicable deductions;

 (d) the total royalty payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; 

(e) the amount of Sublicense Income received by the Company from each Sublicensee and the amount due to PureTech from such Sublicense Income, including an
itemized breakdown of the sources of income comprising the Sublicense Income; and 
 (f) the number of sublicenses entered into for the Patent Rights and/or
Licensed Products. 

 If no amounts are due to PureTech for any Reporting Period, the report shall so state. 

4.3 Financial Statements. On or before the [ *** ] following the close of the Company’s fiscal year, the Company shall provide PureTech with the
Company’s financial statements for the preceding fiscal year including, at a minimum, a balance sheet and an income statement, certified by the Company’s treasurer or chief financial officer or by an independent auditor. 

4.4 Record Keeping. The Company shall maintain, and shall require its Affiliates and any Sublicensees to maintain, complete and accurate records
relating to research and development under this Agreement and any amounts payable to PureTech in relation to this Agreement, which records shall contain sufficient information to permit PureTech to confirm the accuracy of any reports delivered to
PureTech and compliance in other respects with this Agreement. The relevant party shall retain such records for at least [ *** ] following the end of the calendar year to which they pertain, during which time PureTech, or PureTech’s appointed
agents, shall have the right, at PureTech’s expense, to inspect such records during normal business hours upon minimum advance notice of [ *** ] to verify any reports and payments made or compliance in other respects under this Agreement. Any
person inspecting the books and records of the Company on behalf of PureTech pursuant to this Section 4.4 shall enter into a confidentiality agreement with the Company in its standard form covering the receipt of confidential information from
the Company. In the event that any audit performed under this Section reveals an underpayment in excess of [ *** ] the Company shall bear the full cost of such audit. Any auditor shall report to PureTech only the amount of any underpayment or
overpayment to PureTech or that the payments made by the Company were correct. The auditor shall deliver a copy of its audit report to the Company at the same time it remits such audit report to PureTech. The Company shall remit any amounts due to
PureTech. and PureTech shall refund any overpayment to the Company, within [ *** ] of receiving the report of the auditor. 
 5.
PATENT PROSECUTION. 
 5.1 Responsibility for Patent Rights. The Company shall prepare, file, diligently prosecute and maintain all of the
Patent Rights. PureTech shall have reasonable opportunities to advise the Company with respect to such preparation, filing, prosecution and maintenance and PureTech arid the Company shall cooperate with each other (any each other’s respective
legal counsel) in such filing, prosecution and maintenance. 
 5.2 Payment of Expenses. Payment of all fees and costs, including attorneys fees,
incurred after the Effective Date relating to the filing, prosecution and maintenance of the Patent Rights shall be the responsibility of the Company. 

5.3 Reversion of Patent Rights. In its sole discretion, the Company may elect not to prosecute certain of the Patent Rights (including rights in
certain countries or territories) if and only if the Company shall notify PureTech of such decision within [ *** ] prior to any filing deadline in respect of such Patent Rights; provided however that it the Company elects not to prosecute such
Patent Rights, such Patent Rights shall revert to PureTech and shall automatically be excluded from the definition of “Patent Rights” hereunder. 

6. INFRINGEMENT. 
 6.1
Notification of Infringement. Each Party agrees to provide written notice to the other Party promptly after becoming aware of any infringement of the Patent Rights. 

6.2 Right to Prosecute Infringements. 
 (a) Company
Right to Prosecute. So long as the Company remains the exclusive licensee of the Patent Rights in the Field in the Territory, the Company, to the extent permitted by law, shall have the right, under its own control and at its own expense, to
prosecute any third party infringement of the Patent Rights in the Field in the Territory, subject to Section 6.4. If required by law, PureTech shall permit any action under this Section 6.2 to be brought in its name, including being
joined as a party-plaintiff, provided that the Company shall hold PureTech harmless from, and indemnify PureTech against, any costs, expenses, or liability that PureTech incurs in connection with such action. Prior to commencing any such action, the
Company shall consult with PureTech and shall consider the views 

 
of PureTech regarding the advisability of the proposed action and its effects. The Company shall not enter into any settlement, consent judgment, or other voluntary final disposition of any
infringement action under this Section 6.2 which admits the invalidity or unenforceability of any Patent Rights without the prior written consent of PureTech. If the Company does not take commercially reasonable steps to abate the infringement
of such Patent Rights within [ *** ] from any infringement notice from PureTech, based upon the Company’s determination that such action would be commercially unreasonable and the Company provides PureTech its reasons therefor in writing, then
the Company shall not have the obligation to take any such action or institute any proceeding. In this regard, the Company shall be entitled to use its reasonable commercial discretion in determining (a) whether to contact and/or institute any
action or proceeding against an alleged infringer; (b) the timing of any contact with an alleged infringer or action or proceeding to be instituted against an alleged infringer; (c) the location of any action or proceeding to be instituted
against an alleged infringer; and (d) if there is more than one alleged infringer, which alleged infringer to contact regarding its alleged infringement or against which any action or proceeding is to be brought. It is further understood and
agreed that, during such time as the Company is pursuing any action or proceeding against one alleged infringer, the Company shall have no obligation to contact or pursue additional alleged infringers. 

(b) PureTech Right to Prosecute. In the event that the Company is unsuccessful in persuading the alleged infringer to desist or fails to have initiated
an infringement action within the time provided in Section 6.2(a) above and the infringement is open, obvious and financially material, PureTech shall have the right, at its sole discretion, to prosecute such infringement under its sole control
and at its sole expense, and any recovery obtained shall belong to PureTech. 
 6.3 Declaratory Judgment Actions. In the event that a declaratory
judgment action is brought against PureTech or the Company by a third party alleging invalidity, unenforceability, or non-infringement of the Patent Rights, PureTech, at its option, shall have the right within
[ *** ] commencement of such action to take over the sole defense of the action at its own expense. If PureTech does not exercise this right, the Company may take over the sole defense of the action at the Company’s sole expense, subject to
Section 6.4. 
 6.4 Recovery. Any recovery obtained in an action brought by the Company under Sections 6.2 or 6.3 shall be distributed as
follows: (i) each Party shall be reimbursed [ *** ] for any expenses incurred in the action from the proceeds of such action or settlement, (ii) as to ordinary damages, such amount shall be treated as Net Sales, and the Company shall pay
to PureTech based upon such amount a reasonable approximation of the royalties and other amounts that the Company would have paid to PureTech if the Company had sold the infringing products, processes and services rather than the infringer, and
(iii) as to special or punitive damages, the parties shall share equally in any award. Any recovery obtained in an action brought by PureTech under Sections 6.2 or 6.3 shall be distributed as follows: (i) each Party shall be reimbursed [
*** ] for any expenses incurred in the action from the proceeds of such action or settlement and all remaining amounts shall be shared [ *** ] to PureTech and [ *** ] to the Company. 

6.5 Cooperation. Each party agrees to cooperate in any action under this Article which is controlled by the other party, provided that the controlling
party reimburses the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing such assistance. 

6.6 Right to Sublicense. So long as the Company remains the exclusive licensee of the Patent Rights in the Field in the Territory, the Company shall
have the sole right to sublicense any alleged infringer in the Field in the Territory for use of the Patent Rights in accordance with the terms and conditions of this Agreement relating to sublicenses. 

7. INDEMNIFICATION 
 7.1 Indemnity.

 (a) By the Company. The Company shall indemnify, defend, and hold harmless PureTech and its members, directors, officers, employees, agents and
Affiliates and their respective successors, heirs and assigns (the “PureTech Indemnitees”), against any liability, damage, loss, or expense (including reasonable attorneys fees and expenses) incurred by or imposed upon any of the
PureTech Indemnitees in connection with any third party claims, suits, actions, demands or judgments arising out of any theory of liability (including without limitation actions in the form of tort, warranty, or strict liability and regardless of
whether such action has any factual basis) (a “Loss”) 

 
(i) concerning any product, process or service that is made, used, sold, imported or performed pursuant to any right or license granted under this Agreement or (ii) due to a breach of
this Agreement by the Company; provided, however, that the foregoing indemnification shall not apply to any Loss to the extent such Loss is caused by the breach of this Agreement or the gross negligence or willful misconduct of a PureTech
Indemnitee. 
 7.2 Procedures. A party seeking indemnification pursuant to Section 7.1 shall provide the indemnifying Party with prompt written
notice of any claim, suit, action, demand, or judgment for which indemnification is sought under this Agreement. The indemnifying Party, at its own expense, shall provide attorneys reasonably acceptable to the indemnified party to defend against any
such claim. The indemnified party shall cooperate fully with the indemnifying Party in such defense and shall permit the indemnifying Party to conduct and control such defense and the disposition of such claim, suit, or action (including all
decisions relative to litigation, appeal, and settlement); provided, however, that any indemnified party shall have the right to retain its own counsel, at the expense of the indemnifying Party, if representation of such indemnified party by the
counsel retained by the indemnifying Party would be inappropriate because of actual legal conflicts between such indemnified party and any other party represented by such counsel. The indemnifying Party agrees to keep the other Party informed of the
progress in the defense and disposition of such claim and to consult with such Party with regard to any proposed settlement. 
 7.3 Insurance.
Beginning at such time as any such product, process or service is being commercially distributed, sold, leased or otherwise transferred, or performed or used, by the Company, an Affiliate or any Sublicensee, the Company shall, at its sole cost and
expense, procure and maintain commercial general liability insurance in amounts not less than [ *** ] per incident and [ *** ] annual aggregate and naming the Indemnitees as additional insureds. Such commercial general liability insurance shall
provide (i) product liability coverage and (ii) broad form contractual liability coverage for Company’s indemnification under Section 7.1 of this Agreement. If Company elects to self-insure all or part of the limits described
above (including deductibles or retentions which are in excess of [ *** ] annual aggregate) such self-insurance program must be acceptable to the PureTech. The minimum amounts of insurance coverage required under this Section 7.3 shall not be
construed to create a limit of the Company’s liability with respect to its indemnification under Section 7.1 of this Agreement. The Company shall provide PureTech with written evidence of such insurance upon request of PureTech. The
Company shall provide PureTech with written notice at least [ *** ] prior to the cancellation, non-renewal or material change in such insurance; if the Company does obtain replacement insurance providing
comparable coverage prior to the expiration of such [ *** ] period. PureTech shall have the right to terminate this Agreement effective at the end of such [ *** ] period without notice or any additional waiting periods. The Company shall maintain
such commercial general liability insurance beyond the expiration or termination of this Agreement during (i) the period that any such product, process, or service is being commercially distributed, sold, leased or otherwise transferred, or
performed or used (other than for the purpose of obtaining regulatory approvals), by the Company or by a licensee, affiliate or agent of Company and (ii) a reasonable period after the period referred to in (i) above which in no event shall
be less than [ *** ] This section 7.3 shall survive expiration or termination of this Agreement. 
 8. REPRESENTATIONS, WARRANTIES AND
COVENANTS 
 8.1 Representations and Warranties by each Party. Each of PureTech and the Company, with respect to itself, represents, warrants and
covenants to the other that: 
 (a) it is a corporation or entity duly organized and validly existing under the laws of the state or jurisdiction of its
incorporation; 
 (b) the execution, delivery and performance of this Agreement has been duly authorized by all requisite corporate or other action and does
not require any shareholder or member action or approval; 
 (c) it has the full right, power, and authority to enter into and deliver this Agreement, and
that the execution of this Agreement creates a valid and binding Agreement enforceable against it in accordance with its terms; 
 (d) the execution,
delivery, and performance of this Agreement and its compliance with the terms and provisions hereof does not, and will not, conflict with or result in a breach of any of the terms or provisions of, or constitute a default under (i) a loan
agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter or operative documents or
by-laws; or (iii) any order, writ, injunction, or decree of any court or governmental authority entered against it or by which any of its property is bound; and 

 (e) to its knowledge, there are no existing or threatened actions, suits or claims pending against it with
respect to its right to enter into and perform its obligations under this Agreement. 
 8.2 No Further Representations or Warranties; Damages. EXCEPT
AS MAY OTHERWISE BE EXPRESSLY SET FORTH IN THIS AGREEMENT, PURETECH MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING (A) THE PATENT RIGHTS, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, (2) THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, (3) REGARDING THE VALIDITY OR SCOPE OF THE PATENT RIGHTS OR
(4) THAT THE EXPLOITATION OF THE PATENT RIGHTS OR ANY LICENSED PRODUCT WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY. 

IN NO EVENT SHALL EITHER PARTY, ITS MEMBERS, DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY
KIND, INCLUDING ECONOMIC DAMAGES FOR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER SUCH PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. 

9. ASSIGNMENT. 
 Neither Party may assign
this Agreement without the written consent of the other Party, which consent shall not be unreasonably withheld or delayed. Notwithstanding the foregoing, upon written notice to the other Party, either Party may assign this Agreement to a successor
to its business (whether by merger, a sale or other transfer of all or substantially all of its assets, a sale of a controlling interest of its capital stock, or otherwise) which agrees in writing to assume its obligations hereunder. This Agreement
will be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 
 10.
COVENANTS 
 10.1 Compliance with Laws. The Company and its Affiliates and any Sublicensees shall comply in all material respects with all
commercially material applicable local, state, federal, and foreign laws and regulations relating to the development, manufacture, use, and sale of Licensed Products. 

10.2 Export Control. The Company and its Affiliates and any Sublicensees shall comply with all United States laws and regulations controlling the
export of certain commodities and technical data, including without limitation all Export Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the
export of certain types of commodities and technical data to specified countries. The Company hereby gives written assurance that it will comply with, and will require its Affiliates and any Sublicensees to comply with, all United States export
control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or any Sublicensees, and that it will indemnify, defend, and hold PureTech harmless (in accordance with
Section 7) for the consequences of any such violation. 
 10.3 Non-Use of PureTech Name. The Company and
its Affiliates and any Sublicensees shall not use the name of PureTech or any variation, adaptation, or abbreviation thereof, or of any of its employees, or agents, or any trademark owned by PureTech, or any terms of this Agreement in any
promotional material or other public announcement or disclosure without the prior written consent of PureTech, except as may be required by law, stock exchange rule or other securities trading system rule. 

 10.4 Marking of Licensed Products. To the extent commercially feasible and consistent with prevailing
business practices, the Company shall mark, and shall cause its Affiliates and any Sublicensees to mark, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that
applies to such Licensed Product. 
 11. TERMINATION 

11.1 Voluntary Termination by the Company. The Company shall have the right to terminate this Agreement, for any reason, from time to time upon at
least [ *** ] prior written notice to PureTech, such notice to state the date at least [ *** ] in the future upon which termination is to be effective. Within [ *** ] following such termination effective date, the Company shall pay to PureTech all
amounts due to PureTech through such termination effective date. 
 11.2 Termination for Default. 

(a) Nonpayment. In the event the Company fails to pay any amounts due and payable to PureTech hereunder, and fails to make such payments within [ *** ]
after receiving written notice (by certified US mail) of such failure, PureTech may terminate this Agreement immediately upon written notice to the Company. 

(b) Material Breach by the Company. In the event the Company commits a material breach of its obligations under this Agreement, including a breach of
any of the obligations set forth in Section 2.4 and not including for a breach as described in Section 11.2(a), and fails to cure that breach within [ *** ] after receiving written notice thereof (by certified US mail), PureTech may
terminate this Agreement immediately upon written notice to the Company. 
 (c) Material Breach by PureTech. In the event PureTech commits a material
breach of its obligations under this Agreement and fails to cure that breach within [ *** ] after receiving written notice thereof (by certified US mail), the Company may terminate this Agreement immediately upon written notice to PureTech. 

11.3 Effect of Termination. 
 (a) Survival. The
following provisions shall survive the expiration or termination of this Agreement: Articles 1, 3 (to the extent necessary to satisfy Section 11.3(b) and (c)), (4 to the extent necessary to provide final reports), 7, 9, 10, 11, 12 and 13. 

(b) Inventory. Upon the early termination of this Agreement, the Company and its Affiliates and any Sublicensees may complete and sell any work-in-progress and inventory of Licensed Products that exist as of the Effective Date of termination, provided that (i) the Company pays PureTech the applicable running
royalty or other amounts due on such sales of Licensed Products in accordance with the terms and conditions of this Agreement, and (ii) the Company and its Affiliates and any Sublicensees shall complete and sell all work-in-progress and inventory of Licensed Products within six (6) months after the Effective Date of termination. 

(c) Pre-termination Obligations. In no event shall termination of this Agreement release the Company, its
Affiliates, or any Sublicensees from the obligation to pay any amounts that became due on or before the effective date of such termination. 

12. DISPUTE RESOLUTION. 
 12.1
Mandatory Procedures. The Parties agree that any dispute arising out of or relating to this Agreement shall be resolved solely by means of the procedures set forth in this Article, and that such procedures constitute legally binding
obligations that are an essential provision of this Agreement. If either Party fails to observe the procedures of this Article, as may be modified by their written agreement, the other Party may bring an action for specific performance of these
procedures in any court of competent jurisdiction. 

 12.2 Equitable Remedies. Although the procedures specified in this Article are the sole and exclusive
procedures for the resolution of disputes arising out of or relating to this Agreement, either Party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment, such action is necessary to avoid
irreparable harm to itself or to preserve its rights under this Agreement. 
 12.3 Dispute Resolution Procedures. 

(a) Negotiation. In the event of any dispute arising out of or relating to this Agreement, the affected Party shall notify the other Party, and the
Parties shall attempt in good faith to resolve the matter within [ *** ] after the date of such notice (the “Notice Date”). Any disputes not resolved by good faith discussions shall be referred to senior executives of each Party,
who shall meet at a mutually acceptable time and location within [ *** ] after the Notice Date and attempt to negotiate a settlement. 
 (b)
Arbitration. If the matter remains unresolved within [ *** ] after the Notice Date, or if the senior executives fail to meet within [ *** ] after the Notice Date, either Party shall be entitled to submit the matter to binding arbitration
under the commercial arbitration rules of the American Arbitration Association. Any such arbitration shall be conducted by a panel of three arbitrators (the “Arbitration Panel”) and shall be conducted in Boston, Massachusetts.
PureTech on the one hand, and the Company on the other, shall each appoint one arbitrator, and the third arbitrator shall be appointed by the two arbitrators appointed by PureTech and the Company. The Arbitration Panel shall have the authority to
grant specific performance and to allocate between the parties the costs of arbitration in such equitable manner as it shall determine. Judgments upon the award so rendered may be entered in any court having jurisdiction or application may be made
to such court for judicial acceptance of any award and an order of enforcement, as the case may be. 
 13. MISCELLANEOUS. 

13.1 Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent
by hand, recognized national overnight courier, confirmed facsimile transmission or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the parties: 

If to PureTech: Daphne Zohar 
 PureTech Ventures, LLC 

500 Boylston Street, Suite 1400 
 Boston, Massachusetts 02116 

Tel: 617.482.2333 
 Fax: 617.482.3337 

If to the Company: President 
 Karuna Pharmaceuticals, Inc. 

500 Boylston Street, Suite 1040 
 Boston, Massachusetts 02116 

Tel: 617.482.2333 
 Fax: 617.482.3337 

All notices under this Agreement shall be deemed effective upon receipt. A party may change its contact information immediately upon written notice to the
other party in the manner provided in this Section 13.1. 
 13.2 Governing Law. This Agreement and all disputes arising out of or related to
this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Massachusetts, U.S.A., without
regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. 

 13.3 Force Majeure. Neither party will be responsible for delays resulting from causes beyond the
reasonable control of such party, including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues
performance under this Agreement with reasonable dispatch whenever such causes are removed. 
 13.4 Amendment and Waiver. This Agreement may be
amended, supplemented, or otherwise modified only by means of a written instrument signed by both Parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an
agreement to waive any rights or fail to act in any other instance, whether or not similar. 
 13.5 Severability. In the event that any provision of
this Agreement shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the parties shall negotiate in good faith to modify the Agreement to preserve (to
the extent possible) their original intent. If the Parties fail to reach a modified agreement within thirty (30) days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the
procedures set forth in Article 13. While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted by agreement of the parties. 

13.6 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective permitted successors and
assigns. 
 13.7 Headings. All headings are for convenience only and shall not affect the meaning of any provision of this Agreement. 

13.8 Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior
agreements or understandings between the parties relating to its subject matter. 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives. 
 The Effective Date of this Agreement is March 4, 2011. 
  

									
	PURETECH VENTURES LLC	 		 	KARUNA PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Daphne Zohar
	 		 	By:	 	 /s/ Edmund Harrigan

	Name:	 	Daphne Zohar	 		 	Name:	 	Edmund Harrigan MD
	Title:	 	Managing Partner	 		 	Title:	 	Chief Executive Officer

 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [ *** ]) FROM THE EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT NO. 1 TO EXCLUSIVE PATENT
LICENSE AGREEMENT 
 This Amendment No. 1 (“Amendment No. 1”) to the Exclusive Patent License Agreement dated
as of March 1, 2011 (the “Agreement”) by and among PureTech Ventures, LLC, (the “Company”), and Karuna Pharmaceuticals, Inc. (the “licensee”) is entered into on this 1st day of February, 2013 (the
“Amendment No. 1 Effective Date”). For purposes hereof, all capitalized terms used herein but not defined herein shall have the meanings given to them in the Agreement. 

Pursuant to Section 13.4 of the Agreement, the Company and the Licensee hereby agree as follows: 

1. Section 2.4 of the Agreement is hereby deleted and replaced in its entirety as follows: 

Due Diligence Obligations. The Company shall use diligent efforts, and shall cause its Affiliates and any Sublicensees to use diligent efforts, to
develop Licensed Products and to introduce Licensed Products into the commercial market; thereafter, the Company and its Affiliates and any Sublicensees shall maximize the commercial sales of such Licensed Products. Specifically, the Company and its
Affiliates and any Sublicensees shall fulfill the following obligations: 
  

	 	a.	 Within [ *** ] of the Amendment No. 1 Effective Date, the Company shall initiate, defined as first dosing
of patient, a trial using a Licensed Product. 

  

	 	b.	 At any time prior to approval of a Licensed Product by the U.S. Food and Drug Administration, the Company shall
not, for any consecutive [ *** ] period, fail to initiate, defined as first dosing of patient, a human clinical study with a Licensed Product or make a regulatory submission to the U.S. Food and Drug Administration, the European Medicines Evaluation
Agency, or the Japanese Ministry of Health and Welfare seeking the marketing of a License Product for the treatment of a disease. 

  

	 	c.	 The Company shall not (i) become insolvent; (ii) make an assignment for the benefit of creditors; or
(iii) have a bona fide petition in bankruptcy filed for or against it, which petition is withdrawn or dismissed within [ *** ] of its filing. 

In the event that PureTech determines that the Company (or an Affiliate or Sublicensee) has failed to fulfill its obligations under this Section 2.4,
then PureTech may treat such failure as a material breach in accordance with Section 11.2(b). 
 2. The parties agree that the Agreement is in full
force and effect as of the Amendment No. 1 Effective Date, as amended as set forth above. 
 IN WITNESS WHEREOF, the parties have caused this Amendment
No. 1 to be executed by their duly authorized representatives as of the Amendment No. 1 Effective Date. 
  

			
	Karuna Pharmaceuticals, Inc.
		
	By:	 	/s/ Eric Elenko
	Name:	 	Eric Elenko
	Title:	 	Director

  

			
	PureTech Ventures, LLC
		
	By:	 	/s/ Stephen Muniz
	Name:	 	Stephen Muniz
	Title:	 	Partner

 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [ *** ]) FROM THE EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT NO. 2 TO EXCLUSIVE PATENT
LICENSE AGREEMENT 
 This Amendment No. 2 (“Amendment No. 2”) to the Exclusive Patent License Agreement dated
as of March 4, 2011 (the “Agreement”) by and among PureTech Ventures, LLC (the “Company”), and Karuna Pharmaceuticals, Inc. (the “licensee”) is entered into on this 25th day of February, 2015 (the
“Amendment No. 2 Effective Date”). For purposes hereof, all capitalized terms used herein but not defined herein shall have the meanings given to them in the Agreement. 

Pursuant to Section 13.4 of the Agreement, the Company and the Licensee hereby agree as follows: 

1. Section 2.4 of the Agreement, which was first amended by Amendment No. 1 to Exclusive License Agreement dated February 1, 2013
(“Amendment No. 1”), which Amendment No. 1 deleted and replaced Section 2.4 in its entirety is hereby deleted and replaced in its entirety a second time to read as follows: 

Due Diligence Obligations. The Company shall use diligent efforts, and shall cause its Affiliates and any Sublicensees to use diligent efforts, to
develop Licensed Products and to introduce Licensed Products into the commercial market; thereafter, the Company and its Affiliates and any Sublicensees shall maximize the commercial sales of such Licensed Products. Specifically, the Company and its
Affiliates and any Sublicensees shall fulfill the following obligations: 
  

	 	a.	 Within [ *** ] of the Amendment No. 2 Effective Date, the Company shall initiate, defined as first dosing
of patient, a trial using a Licensed Product. 

  

	 	b.	 At any time prior to approval of a Licensed Product by the U.S. Food and Drug Administration, the Company shall
not, for any consecutive [ *** ] period, fail to initiate, defined as first dosing of patient, a human clinical study with a Licensed Product or make a regulatory submission to the U.S. Food and Drug Administration, the European Medicines Agency, or
the Japanese Ministry of Health, Labour and Welfare seeking the marketing of a Licensed Product for the treatment of a disease. 

  

	 	c.	 The Company shall not (i) become insolvent; (ii) make an assignment for the benefit of creditors; or
(iii) have a bona fide petition in bankruptcy filed for or against it, which petition is withdrawn or dismissed within [ *** ] of its filing. 

In the event that PureTech determines that the Company (or an Affiliate or Sublicensee) has failed to fulfill its obligations under this Section 2.4,
then PureTech may treat such failure as a material breach in accordance with Section 11.2(b).” 
 2. The parties agree that the Agreement is in
full force and effect as of the Amendment No. 2 Effective Date, as amended as set forth above. 

 IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their duly
authorized representatives as of the Amendment No. 2 Effective Date. 
  

			
	Karuna Pharmaceuticals, Inc.
		
	By:	 	/s/ Eric Elenko
	Name:	 	Eric Elenko
	Title:	 	Director

  

			
	PureTech Ventures, LLC
		
	By:	 	/s/ Stephen Muniz
	Name:	 	Stephen Muniz
	Title:	 	Partner

 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [ *** ]) FROM THE EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT NO. 3 TO EXCLUSIVE PATENT
LICENSE AGREEMENT 
 This Amendment No. 3 (“Amendment No. 3”) to the Exclusive Patent License Agreement dated
as of March 4, 2011 (the “Agreement”) by and among PureTech Health LLC (f/k/a PureTech Ventures, LLC) (“PureTech”), and Karuna Pharmaceuticals, Inc. (the “Company”), as previously amended by
Amendment No. 1 to Exclusive License Agreement dated February 1, 2013 (“Amendment No. 1”) and Amendment No. 2 to Exclusive License Agreement dated February 25, 2015 (“Amendment
No. 2”), is entered into effective as of July 31, 2015 (the “Amendment No. 3 Effective Date”). For purposes hereof, all capitalized terms used herein but not defined herein shall
have the meanings given to them in the Agreement. 
 Pursuant to Section 13.4 of the Agreement, PureTech and the Company hereby agree as follows: 

1. Section 5.3 of the Agreement, as amended pursuant to Amendment 1 and Amendment 2, is hereby deleted and replaced in its entirety to read as follows:

 “5.3 Reversion of Patent Rights. The Company may elect not to prosecute certain of the Patent Rights (including rights in certain countries or
territories). If (i) the Company has elected not to prosecute any such Patent Rights, and (ii) any third party with a binding contractual right to prosecute such Patent Rights on behalf of the Company has waived or otherwise affirmatively
elected not to exercise such right, then the Company may notify PureTech of the same and upon such notice such Patent Rights shall automatically revert to PureTech and be excluded from the definition of “Patent Rights” hereunder.”

 2. PureTech and the Company agree that the Agreement, as amended by Amendment No. 1 and Amendment No. 2, is in full force and effect as of the
Amendment No. 3 Effective Date as amended as set forth herein. 
 IN WITNESS WHEREOF, the undersigned parties have caused this Amendment No. 3 to
be executed by their duly authorized representatives as of the Amendment No. 3 Effective Date. 
  

			
	KARUNA PHARMACEUTICALS, INC.

 
			
		
	By:	 	/s/ Eric Elenko
	Name:	 	Eric Elenko
	Title:	 	President

  

			
	PURETECH HEALTH LLC
		
	By:	 	/s/ Stephen Muniz
	Name:	 	Stephen Muniz
	Title:	 	EVP, Legal, Finance & OperationsEX-10.12

 Exhibit 10.12 

DATED 18 June 2015 
 (1) PURETECH HEALTH PLC

 - and- 
 (2) INVESCO ASSET
MANAGEMENT LIMITED 
 (ACTING AS AGENT FOR AND ON BEHALF OF ITS 

DISCRETIONARY MANAGED CLIENTS) 

RELATIONSHIP AGREEMENT 

 CONTENTS 
  

							
	1.	  	DEFINITIONS AND INTERPRETATION	  	 	2	 
	2.	  	CONDITION PRECEDENT	  	 	5	 
	3.	  	CONDUCT OF TRANSACTIONS AND RELATIONSHIPS	  	 	5	 
	4.	  	INFORMATION COVENANT	  	 	6	 
	5.	  	CONFIDENTIAL INFORMATION	  	 	6	 
	6.	  	ANNOUNCEMENTS	  	 	8	 
	7.	  	OVERRIDING OBLIGATIONS	  	 	8	 
	8.	  	TERMINATION OF DEED	  	 	8	 
	9.	  	VARIATION, WAIYER AND CONSENT	  	 	9	 
	10.	  	FURTHER ASSURANCE	  	 	9	 
	11.	  	ASSIGNMENT	  	 	9	 
	12.	  	SEVERABILITY	  	 	9	 
	13.	  	ENTIRE AGREEMENT	  	 	9	 
	14.	  	GOVERNING LAW AND JURISDICTION	  	 	10	 
	15.	  	NOTICES	  	 	10	 
	16.	  	COUNTERPARTS	  	 	11	 
	17.	  	COSTS	  	 	11	 
	18.	  	NOPARTNERSHIPORAGENCY	  	 	11	 
	19.	  	THIRD PARTY RIGHTS	  	 	11	 

 THIS DEED is made on 

18 June 2015 
 BETWEEN: 

 

	(1)	 PURETECH HEALTH PLC, a company incorporated in England and Wales with company number 09582467, whose
registered office is at 5th Floor, 6 St Andrew Street, London EC4A 3AE, United Kingdom (“Company”); and 

  

	(2)	 INVESCO ASSET MANAGEMENT LIMITED, a company incorporated in England and Wales with company number
00949417, whose registered office is at Perpetual Park, Perpetual Park Drive, Henley-On-Thames, Oxfordshire, RG9 IHH United Kingdom (“ Shareholder”).

 RECITALS: 
  

	A	 Application has been made or will be made by the Company for all of the Ordinary Shares to be admitted to the
Official List and to be admitted to trading on the main market for listed securities of the London Stock Exchange (“Admission”). 

  

	B	 It is expected that upon Admission the Shareholder will exercise or control on its own or together with certain
of its associates, and together with any person with whom they are acting in concert (or deemed to be acting in concert), more than 30 per cent. of the votes able to be cast on all or substantially all matters at general meetings of the
Company. 

  

	C	 In contemplation of Admission, the Company and the Shareholder have agreed to enter into this Deed to record
the current and future basis of the Shareholder’s relationship with the Company as a Controlling Shareholder so that the Company can demonstrate that there are appropriate measures in place to regulate their relationship and to deliver
effective independence. Furthermore, the Company wishes to enter into this Deed with the Shareholder pursuant to LR 6.1.4BR which includes a requirement for the Company, as a company with a Controlling Shareholder admitted to listing on the premium
listing segment of the Official List, to have in place a written and legally binding agreement with such Controlling Shareholder containing certain provisions intended to ensure that the independence of the Company is safeguarded.

 IT IS AGREED: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 Definitions 

In this Deed, the following words, expressions and abbreviations shall have the following meanings (except where the context otherwise
requires): 
 “acting in concert” means acting together with another entity (or a number of entities) to control or exercise
30 per cent. or more of the votes able to be cast on all or substantially all matters at general meetings of the Company as referred to in the context of Chapter 6 of the Listing Rules and the definition of “controlling shareholder”
in the Listing Rules; 
 “Admission” shall have the meaning ascribed to it in recital A of this Deed; 

“Announcements” means any press announcement by the Company in connection with Admission; 

  
 2 

 “Articles” mean the articles of association of the Company as amended from
time to time; 
 “Associate” means any legal or natural person which falls within the definition of an Associate in the
Listing Rules; 
 “Business Day” means any day (other than a Saturday or Sunday or public holiday) on which banks generally
are open in the City of London for the transaction of normal banking business; 
 “CJA” means the Criminal Justice
Act 1993; 
 “Companies Law” means the Companies Act 2006; 

“Company Group” means the Company, its subsidiary undertakings and its operating companies from time to time and references to
a “member of the Company Group” shall be construed accordingly; 
 “Confidential Information” has the meaning set
out in clause 5.4; 
 “Controlling Shareholder” has the meaning given to the definition of “controlling
shareholder” in the Listing Rules; 
 “Disclosure and Transparency Rules” means the rules made by the FCA relating to
the disclosure of information pursuant to Part VI of the FSMA; 
 “FCA” means the UK Financial Conduct Authority or its
successor in respect of the regulation of listed companies and securities; 
 “FSMA” means the Financial Services and
Markets Act 2000 (as amended from time to time); 
 “Invesco Funds” means Invesco Perpetual Income Fund, Invesco Perpetual
High Income Fund, Invesco Perpetual UK Equity Pension Fund, Invesco Perpetual UK Strategic Income Fund and Invesco Perpetual Distribution Fund; 

“Listing Rules” means the listing rules made by the FCA pursuant to Part VI of the FSMA; 

“London Stock Exchange” means the London Stock Exchange pie; 

“Minimum Interest” means an interest of 30 per cent or more of the issued share capital of the Company (or which carries
30 per cent or more of the aggregate Voting Rights in the Company from time to time); 
 “Official List” means the
official list maintained by the FCA; 
 “Ordinary Share” means an ordinary share in the capital of the Company having the
rights set out in the A11icles; 
 “Prospectus” means the document prepared by the Company in connection with Admission and
to be approved by the FCA in accordance with the Listing Rules; 
 “Prospectus Rules” means the prospectus rules made by the
FCA pursuant to Part VI of the FSMA; 

  
 3 

 “subsidiary undertaking” means, in relation to a company, any subsidiary
undertaking of such company as defined in section 1162 of the Companies Act 2006 and “subsidiaries” shall mean all subsidiary undertakings of such company; 

“Takeover Code” means the City Code on Takeovers and Mergers or any successor code or other regime (whether statutory or non-statutory) governing the conduct of takeovers and mergers in the United Kingdom; 

“undertaking” means a company, body corporate, partnership, joint venture or other economic enterprise (whether or not a body
corporate) carrying on a business (whether or not for profit); and 
 “Voting Rights” means, in relation to any undertaking,
voting rights attaching to securities of the relevant undertaking which are generally exercisable at meetings of security holders of the relevant undertaking. 
  

	1.2	 Interpretation 

In this Deed (except where the context otherwise requires): 
  

	 	1.2.1	 clause and paragraph headings and any table of contents are inserted for ease of reference only and shall not
affect construction; 

  

	 	1.2.2	 any reference to a “party” is to a party to this Deed; 

 

	 	1.2.3	 any reference to a recital or clause is to the relevant recital or clause to this Deed; 

 

	 	1.2.4	 any reference to “include” or “including” (or any similar term) is not to be
construed as implying any limitation and general words introduced by the word “other” (or any similar term) shall not be given a restrictive meaning by reason of the fact that they are preceded by words indicating a particular class
of acts, matters or things; 

  

	 	1.2.5	 any reference to a person shall include any individual, firm, body corporate, association, joint venture,
partnership, government, state or agency of state, in each case whether or not having a separate legal personality. Reference to a company shall be construed so as to include any company, corporation or other body corporate wherever and however
incorporated or established; 

  

	 	1.2.6	 references to the Prospectus Rules, the Listing Rules, the Disclosure and Transparency Rules, the Companies
Law, the Takeover Code, the CJA and the FSMA and to any statutes or statutory provisions include any code, regulation, statute or statutory provision which amends, extends, consolidates or replaces the same, or which has been amended, extended,
consolidated or replaced by the same, and shall include any orders, regulations, instruments or other subordinate legislation made under the relevant statute or statutory provision; 

 

	 	1.2.7	 any reference to a deed or other document or any provisions thereof is a reference thereto as it is in force
for the time being and from time to time as amended, supplemented, novated, or replaced; 

  

	 	1.2.8	 all representations, warranties, covenants, undertakings and obligations in this Deed given to or enforceable
by the Shareholder shall be deemed also to have been given to and be enforceable separately by each of the Invesco Funds and/or by the Shareholder on behalf of the Invesco Funds. 

  
 4 

	 	1.2.9	 any reference to “writing” or “written” includes any method of reproducing
words or text in a legible and non-transitory form but, for the avoidance of doubt, shall not include email; and 

  

	 	1.2.10	 references to times of the day are to the time in London in the United Kingdom. 

 

	2.	 CONDITION PRECEDENT 

 

	2.1	 Deed conditional upon Admission 

This Deed is conditional upon, and shall come into force on, Admission (the “Condition Precedent”). 

 

	2.2	 Long stop date 

In the event that Admission has not occurred on or before 30 June 2015 (or such later date as is agreed between the parties in writing),
this Deed shall be null and void and of no further force or effect and no party shall have any claim in respect of this Deed against any other party for costs, damages, compensation or otherwise. 

 

	3.	 CONDUCT OF TRANSACTIONS AND RELATIONSHIPS 

 

	3.1	 The Shareholder shall and shall procure that each of its Associates and any person with whom they are acting in
concert shall: 

  

	 	3.1.1	 make and conduct all transactions, agreements and relationships with the Company and any other member of the
Company Group at arm’s length and on normal commercial terms (and the parties hereby acknowledge that this Deed has been concluded on such a basis); 

  

	 	3.1.2	 not take any action that would, or would be reasonably likely to, have the effect of preventing the Company or
any other member of the Company Group from complying with its obligations under the Listing Rules; 

  

	 	3.1.3	 not propose or procure the proposal of a shareholder resolution which is intended or appears to be intended to
circumvent the proper application of the Listing Rules; and 

  

	 	3.1.4	 not exercise any of its voting or other rights and powers: 

 

	 	3.1.4.1	 to procure or propose, or vote in favour of, any resolution for any amendment to the Articles of the Company
which would be inconsistent with, undermine or breach any of the provisions of this Deed or the Listing Rules or would be contrary to the principle of the independence of the Company from the Shareholder and its Associates; or

  

	 	3.1.4.2	 in a manner which would be inconsistent with, or breach any of the provisions of, this Deed, the Listing Rules
or the Disclosure and Transparency Rules. 

  
 5 

	3.2	 Where any obligations that the Company is in the future required to impose on the Controlling Shareholder (or
its Associates or persons with whom it is acting in concert) to ensure that the Listing Rules (if amended) are complied with in full are not satisfied under the terms of this Deed, the parties agree to negotiate in good faith to amend the terms of
this Deed to give effect to the Listing Rules (as amended). 

  

	3.3	 Nothing in this Deed is intended to prevent the Shareholder, any of its Associates or persons with whom it is
acting in concert, from acquiring or disposing of any securities of the Company (save to the extent otherwise required by law or regulation). 

  

	4.	 INFORMATION COVENANT 

 

	4.1	 The Shareholder acknowledges that, pursuant to Listing Rule 9.8.4R(l4), the Company will be required to include
in each annual financial report certain statements made by the Board confirming that amongst other things: 

  

	 	4.1.1	 the Company has entered into all agreements required under Listing Rule 9.2.2AR; and 

 

	 	4.1.2	 the Company has complied with the independence provisions set out in Clauses 3. I. I to 3.1.4 above throughout
the accounting period covered by the annual financial report, 

 or else to confirm that the FCA has been notified and to
include statements to the effect that such agreements have not been entered into and/or complied with and a description of the reasons therefor to enable shareholders to evaluate the impact of non-compliance,
as the case may be. 
  

	4.2	 The Shareholder covenants to provide all information (as to the compliance of itself and/or any member of the
Shareholder group with the requirements of Clause 3.1) within a reasonable timeframe that may be reasonably requested by or on behalf of the Board in order to support the statements required to be made by the Board as described in Clause 4.1.

  

	5.	 CONFIDENTIAL INFORMATION 

 

	5.1	 The Shareholder shall ensure that any Confidential Information (as hereinafter defined) which it acquires in
connection with this Deed shall be treated as confidential by it. 

  

	5.2	 Subject to the exceptions stated in clause 5.3, the Shareholder shall not disclose or use Confidential
Information for any purpose whatsoever other than for the purposes of properly performing its obligations under this Deed. 

  

	5.3	 Confidential Information shall be maintained as confidential by the Shareholder and may only be disclosed:

  

	 	5.3.1	 to such of its Associates and its or their respective employees, officers, directors and/or members who
reasonably require such disclosure (on the basis that such person(s) are required to comply with this clause 5.3 as if they were subject to these obligations); 

 

	 	5.3.2	 to its legal, accounting, insurance and other professional advisers (on the basis that such person(s) are
required to comply with this clause 5 as if they were subject to these obligations); 

  
 6 

	 	5.3.3	 to the tax or VAT authorities, any regulatory authority, and any other governmental or public authority or
officer, but only to the extent that such persons require such disclosure for the proper discharge of their functions; 

  

	 	5.3.4	 where required, in connection with any legal proceedings; and 

 

	 	5.3.5	 in compliance with any law or regulation, or if required by or for the purpose of listing, or maintaining a
listing of securities on, or complying with the rules of any stock exchange. 

  

	5.4	 For the purpose of this Deed, “Confidential Information” means any information of a secret,
price sensitive or confidential nature acquired from and concerning the Company Group from time to time or its affairs, whether in written or oral form, save that the Shareholder shall not be obliged to maintain in confidence any such information if
the information: 

  

	 	5.4.1	 was in the possession of or was known to the Shareholder prior to its receipt from the Company (other than
through a breach of this clause 5); or 

  

	 	5.4.2	 is independently developed or acquired by the Shareholder without the utilisation of such Confidential
Information; or 

  

	 	5.4.3	 is or becomes public knowledge without the fault of the Shareholder; or 

 

	 	5.4.4	 is or becomes available to the Shareholder from a source other than the Company. in circumstances where the
Shareholder concerned is not aware that disclosure has been made in breach of an obligation of confidentiality. 

  

	5.5	 The Shareholder agrees and unde1takes to the Company that it will procure so far as 1t 1s reasonably able that
its permitted disclosees as set out in clause 5.3 treat all Confidential Information which comes into the possession of such persons as confidential. 

  

	6.	 INSIDE INFORMATION 

 

	6.1	 The Shareholder acknowledges that the information disclosed to it by or on behalf of the Company or any other
member of the Company Group may be inside information in relation to the Ordinary Shares for the purposes of the CJA and/or the FSMA and accordingly the Shareholder undertakes that it shall not (and shall use all reasonable endeavours to procure
that none of its Associates or any person with whom it is acting in concert shall not): 

  

	 	6.1.1	 deal in securities that are price affected securities (as defined in the CJA) in relation to such inside
information, encourage another person to deal in price affected securities or disclose the information except as permitted by the CJA, in each case before the inside information is made public; 

 

	 	6.1.2	 deal or attempt to deal in a qualifying investment or related investment (as defined in the FSMA) on the basis
of such inside information; 

  

	 	6.1.3	 engage in behaviour based on any such inside information which would amount to market abuse for the purposes of
the FSMA; or 

  

	 	6.1.4	 otherwise breach the requirements of any laws, rules and regulations in relation to dealings in the
Company’s securities which apply to the Shareholder, any of its Associates or any person with whom it is acting in concert. 

  
 7 

	7.	 ANNOUNCEMENTS 

Except for (i) the Prospectus and any preliminary or supplementary documents thereto; (ii) any Announcements; and (iii) the
documents relating to the Admission and identified in the Prospectus (or any preliminary or supplementary documents thereto) as to be made available on display by the Company pursuant to the Prospectus Rules, no party shall make, and shall use all
reasonable endeavours to procure that none of such party’s Associates makes, any announcement or publish any circular in connection with the existence or the subject matter of this Deed or referring to any other party without the prior written
approval of the other party. This shall not affect any announcement or circular required by law or any regulatory body or the rules of the London Stock Exchange, but a party with an obligation to make an announcement or issue a circular shall
consult with the other party insofar as is reasonably practicable as to the content, timing and manner of such an announcement or circular before complying with such an obligation. 

 

	8.	 OVERRIDING OBLIGATIONS 

 

	8.1	 For the avoidance of doubt, the obligations of each of the parties pursuant to this Deed shall at all
times be subject to all relevant legal and regulatory requirements and obligations of the United Kingdom, including, without limitation, the obligations of the parties in the United Kingdom or elsewhere including, without limitation, the
requirements of the Disclosure and Transparency Rules, the Listing Rules, the Prospectus Rules, the Companies Law, the Takeover Code, the FCA, the CJA, the FSMA and the London Stock Exchange. Each party shall act in accordance with each of such
requirements and obligations applicable to it and no party shall be required to take any action in breach of any such requirement or obligation applicable to it. 

 

	8.2	 In the event of any conflict between the prov1s10ns of this Deed and the Articles, the provisions of
this Deed shall prevail as between the parties to the extent permitted by applicable law and regulation. 

  

	9.	 TERMINATION OF DEED 

 

	9.1	 This Deed shall come into force upon satisfaction of the Condition Precedent and shall continue in full force
and effect for so long as the Shareholder, any of its Associates and any person with whom it is acting in conceit, in aggregate hold a Minimum Interest or is othe1wise a Controlling Shareholder, save that the termination and cessation of this Deed
shall not relieve any party from any liability or obligation in respect of any matters, unde1takings or conditions which shall not have been done, observed or performed by that party prior to such termination. 

 

	9.2	 This Deed shall terminate immediately upon the cancellation of Admission whereupon, other than in relation to
any pre-existing breach of any provision of this Deed, no party shall have any rights or obligations under this Deed. 

  

	9.3	 The Shareholder may terminate this Deed immediately at any time by notice to the Company if the Company has a
receiver, administrative receiver, administrator or manager appointed over the whole or the majority of it or its assets or business, makes any composition or arrangement with its creditors or an order or resolution is made for its dissolution or
liquidation (other than for the purpose of solvent amalgamation or reconstruction), or takes or suffers any similar or analogous procedure, action or event in consequence of debt in any jurisdiction. 

 

	9.4	 Clauses I, 4, 6, 9.4 and 10 to 20 shall survive the termination of this Deed for any reason.

  
 8 

	10.	 VARIATION, WAIVER AND CONSENT 

 

	10.1	 No variation or waiver of any provision or condition of this Deed shall be effective unless it is in
writing and signed by or on behalf of each of the parties (or, in the case of a waiver, by or on behalf of the party waiving compliance). 

  

	10.2	 Unless expressly agreed, no variation or waiver of any provision or condition of this Deed shall
constitute a general variation or waiver of any provision or condition of this Deed, nor shall it affect any rights, obligations or liabilities under or pursuant to this Deed which have already accrued up to the date of variation or waiver, and the
rights and obligations of the parties under or pursuant to this Deed shall remain in full force and effect, except and only to the extent that they are so varied or waived. 

 

	10.3	 Any consent granted under this Deed shall be effective only if given in writing and signed by the
consenting party and then only in the instance and for the purpose for which it was given. 

  

	11.	 FURTHER ASSURANCE 

At any time after the date of this Deed, the Shareholder shall, and shall procure that any necessary third party shall, execute such documents
and do such acts and things as the Company may reasonably require for the purpose of giving the Company the full benefit of all the provisions of this Deed in relation to the obligations of the Shareholder. 

 

	12.	 ASSIGNMENT 

The rights and benefits of this Deed (together with any cause of action arising in connection with any of them) may not be assigned by any
party to any other person without the prior written consent of the other party. 
  

	13.	 SEVERABILITY 

  

	13.1	 Each provision of this Deed is severable and distinct from the others. The Shareholder and the Company
intend that every such provision shall be and remain valid and enforceable to the fullest extent permitted by law. If any such provision is or at any time becomes to any extent invalid, illegal or unenforceable under any enactment or rule of law, it
shall to that extent be deemed not to form part of this Deed but (except to that extent in the case of that provision) it and all other provisions of this Deed shall continue in full force and effect. 

 

	13.2	 In particular, but without prejudice to the generality of the foregoing, the provisions of clause 3 are
believed by both the Shareholder and the Company to be reasonable and legitimate to protect the interests of the Company. If any such provision is subsequently judged to be invalid or unenforceable, but would have been enforceable had it been
subject to some restriction in duration or geographical scope, then the provision will take effect subject to such restriction. 

  

	14.	 ENTIRE AGREEMENT 

 

	14.1	 This Deed together with the Articles constitutes the entire agreement and supersedes any previous
agreements between the parties relating to its subject matter. 

  

	14.2	 Each party acknowledges and agrees that no representations were made which are not set out in this Deed
but that, if any were made, it has not relied on, or been induced to enter into this Deed by, any information, statements, warranties or representations of any description, whether written or oral, made, supplied or given by or on behalf of the
other party in relation to the subject matter of this Deed or otherwise. 

  
 9 

	15.	 GOVERNING LAW AND JURISDICTION 

 

	15.1	 This Deed and any dispute or claim arising out of or in connection with this Deed, its subject matter or
formation (including any non-contractual dispute or claim) are governed by and shall be construed in accordance with English Law. 

 

	15.2	 Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to
settle any dispute or claim arising out of or in connection with this Deed, its subject matter or formation (including any non-contractual dispute or claim). 

 

	16.	 NOTICES 

  

	16.1	 Method of serving notice 

Any notice, demand or other communication (“Notice”) to be given by one party to any other party under this Deed shall be in
the English language in writing and signed by or on behalf of the party giving it. It shall be served by sending it by fax to the number set out in clause 16.2 and marked for the attention of the relevant addressee set out in clause 16.2 (or as
otherwise notified from time to time in accordance with the provisions of this clause I6.1), provided always that a copy of such Notice shall also be sent by email for information purposes only. Any notice so served by fax (and copied by email)
shall be deemed to have been duly given: 
  

	 	16.1.1	 in the case of fax, at the time of transmission; 

 

	 	16.1.2	 in the case of email, at the expiration of two hours after the time the email was sent,

 provided that in each case where delivery by fax or email occurs after 6.00 p.m. on a Business Day or on a day which is
not a Business Day, service shall be deemed to occur at 9.00 a.m. on the next following Business Day. 
  

	16.2	 Addresses for service 

The fax number and email address of the parties for the purpose of clause 16.1 are as follows: 

 

					
		  	Company:	  	PureTech Health plc, Attention of Stephen Muniz
			
		  	Fax:	  	+] 617 482 3337
			
		  	Email:	  	sm@puretechhealth.com
			
		  	Shareholder:	  	Invesco Asset Management Limited, Attention of Charles Henderson
			
		  	Fax:	  	+44(0) 1491416000
			
		  	Email:	  	Charles_Henderson@invescoperpetual.co.uk

  
 10 

	16.3	 Changes of details 

A pa11y may notify any other party to this Deed of a change to its name, fax number or email for the purposes of clause 16.1 provided that,
such notice shall only be effective on: 
  

	 	16.3.1	 the date specified in the notice as the date on which the change is to take place; or 

 

	 	16.3.2	 if no date is specified or the date specified is less than five Business Days after the date on which notice is
given, the date following five Business Days after notice of any change has been given. 

  

	16.4	 Proof of service 

In proving such service it shall be sufficient to prove that (i) the fax transmission was made and a fax confirmation report was received,
and/or (ii) in the case of email, that such email was properly addressed. For the avoidance of doubt, no notice or other communications to any party may be delivered by email only. 

 

	17.	 COUNTERPARTS 

This Deed may be executed in any number of counterpat1s and by the parties to it on separate counterparts and each such counterpart shall
constitute an original of this Deed but all of which together constitute one and the same instrument. This Deed shall not be effective until each pat1y has executed at least one counterpart. 

 

	18.	 COSTS 

Each party shall be responsible for its own legal, accountancy and other costs, charges and expenses incurred in connection with the
negotiation, preparation, execution and implementation by it of this Deed and any document referred to in it. 
  

	19.	 NO PARTNERSHIP OR AGENCY 

No provision of this Deed creates a partnership between the parties or makes a party the agent of the other pai1ies for any purpose. A party
has no authority to bind, to contract in the name of or to create a liability for the other parties in any way or for any purpose and no party shall hold itself out as having authority to do the same. 

 

	20.	 THIRD PARTY RIGHTS 

Save as set out in Clause 1.2.8, the operation of the Contracts (Rights of Third Parties) Act 1999 is hereby excluded in relation to this Deed
and a person who is not a Party to this Deed shall have no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any of its terms. 

IN WITNESS of which this Deed has been executed and has been delivered on the date which appears above. 

  
 11 

			
	 Executed as a deed by
PURETECH                       )

HEALTH PLC by a director in the presence         )

of a
witness:                                        
                     )

                          
                                         
              )
	  	Signature: /s/ Stephen Muniz
		
		  	 Name (block capitals): STEPHEN MUNIZ

Director

		
	Witness signature /s/ Caroline Magor	  	
		
	Witness name (block capitals) CAROLINE MAGOR	  	
		
	Witness address: DLA Piper UK LLP	  	
	 3 Noble Street
	  	
	 London EC2V 7EE
	  	
		
	 Executed as a deed by INVESCO ASSET             )
MANAGEMENT
LIMITED acting as agent       )

 for and on behalf of its discretionary
managed       )

 clients by a director in the presence of
a                 )
 witness:
	  	Signature: /s/ Graeme Proudfoot
		
		  	 Name (block capitals): Graeme Proudfoot

Director

		
	Witness signature: /s/ Beverly Young	  	
		
	Witness name: Beverly Young	  	
	(block capitals)	  	
		
	Witness address: 125 London Wall	  	
	 London, EC2Y SAS
	  	

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]